NPP BrainPod

Neuropsychopharmacology Podcast

Author: Springer Nature

BrainPod is the podcast from the journal Neuropsychopharmacology, produced in association with Nature Publishing Group. Join us as we delve into the latest basic and clinical research that advance our understanding of the brain and behavior, featuring highlighted content from a top journal in fields of neuroscience, psychiatry, and pharmacology. For complete access to the original papers and reviews featured in this podcast, subscribe to Neuropsychopharmacology. Hosted on Acast. See acast.com/privacy for more information.
Be a guest on this podcast

Language: en

Genres: Science

Contact email: Get it

Feed URL: Get it

iTunes ID: Get it

Get all podcast data

Listen Now...

Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical records
Wednesday, 4 June, 2025

Attention deficit hyperactivity disorder, or ADHD, is a common condition that, for a lot of people, is difficult to treat. The drugs that exist have a number of adverse side effects, and about 25 percent of patients don’t respond to existing drugs. And so a team of researchers in Iceland, led by Karl Karlsson, professor of biomolecular engineering at Reykjavik University, undertook a number of different steps to narrow in on and then test what the team has determined to be a novel treatment for ADHD, using an existing drug, amlodipine. Read the full study here: https://www.nature.com/articles/s41386-025-02062-x Hosted on Acast. See acast.com/privacy for more information.